Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
Open Access
- 1 November 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 10043-10055
Abstract
Introduction: Immune-based and antibody-drug conjugate therapies have shown promise in the treatment of patients with small cell lung cancer (SCLC). However, better predictive biomarkers are needed for selection of the appropriate SCLC patients for these advanced therapies and also for evaluation of the efficacy of these treatments. Objective: The aim of this study was to examine the expression of delta-like protein 3 (DLL3), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and mesothelin (MSTN) in patients with SCLC and compare them with those patients’ clinical characteristics. Methods: Immunohistochemical analyses of DLL3, CTLA-4 and MSTN expression were performed in 38 samples from patients with SCLC. Results: We found that positive expression in patients of the biomarkers was as follows: for DLL3, 100% (38/38), for CTLA-4, 89.5% (36/38) and for MSTN 81.5% (31/38). The median survival time was 17.9 months in the DLL3 high expression group and 23 months in the DLL3 low expression group. Patients with a high expression of DLL3 showed a poorer prognosis than those with a low expression of DLL3 (HR=3.4; 95% CI, 1.34–8.6; p=0.01). Conclusion: The expression of DLL3, CTLA-4 and MSTN was not correlated with patients’ age, sex, smoking status, stage, and tumor metastasis. The fact that there was a higher expression of DLL3, CTLA-4, and MSTN in SCLC suggested that these molecules could be used as predictive biomarkers for SCLC.Keywords
This publication has 61 references indexed in Scilit:
- Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast CancerClinical Breast Cancer, 2013
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α productionJournal of Translational Medicine, 2013
- A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as BiomarkersPLOS ONE, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Mesothelin, a novel immunotherapy target for triple negative breast cancerBreast Cancer Research and Treatment, 2012
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- Mesothelin expression correlates with prolonged patient survival in gastric cancerJournal of Surgical Oncology, 2011
- Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous CarcinomaClinical Cancer Research, 2006
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994